Christian Laurini

Christian Laurini

Auto-generated profile, based on publicly available information

Christian Laurini

Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2025 in Neurology Genetics
Verified
Journal Article
Open access
CLChristian Laurini
Christian Laurini
FDFEDERICA RACHELE DANTI
FEDERICA RACHELE DANTI
Massimo RussoMassimo Russo
Massimo Russo
STStefano Tozza
Stefano Tozza
Sara MassuccoSara Massucco
Sara Massucco
SPStefano Previtali
Stefano Previtali
Myelin protein zero (MPZ)–related neuropathies include demyelinating CMT1B and later-onset axonal forms (CMT2I/J). CMT1B pathogenic variants act through gain-of-function, destabilizing MPZ and activating the unfolded protein response (UPR), or loss-of-function, disrupting MPZ homomeric interactions in myelin. This study investigates early-onset (<18 years) CMT1B due to MPZ variants in a large Italian cohort, shedding light on clinical progression and genotype-phenotype correlations, with relevance to emerging UPR-targeted therapies. We analyzed cross-sectional clinical and genetic data from 75 patients across 7 Italian centers. MPZ variants were categorized as destabilizing or non-destabilizing based on published data. To explore the relationship between the degree of protein destabilization and clinical severity, missense variants were evaluated for stability alterations using the DUET online tool, with negative ∆∆G values indicating greater destabilization. Statistical correlations between clinical and molecular features were assessed. This study presents a comprehensive clinical characterization of one of the largest cohorts of early-onset MPZ-related neuropathies reported to date. The Charcot-Marie-Tooth Examination Score (CMTES) correlated with age at assessment (rs = 0.56; p < 0.001), suggesting disease progression in this cohort. Destabilizing variants were associated with earlier onset (p < 0.001), upper limb involvement (p < 0.001), impaired ambulation (p < 0.01), scoliosis (p < 0.01), and faster progression as measured by CMTES/age (0.24 vs 0.11 CMTES/year). After excluding the c.245A>C, p.Y82S outlier (highly destabilizing but not UPR-activating), ∆∆G values showed significant correlations with age at onset (rs = 0.54, p = 0.030), CMTES (rs = −0.82, p < 0.001), and progression (rs = −0.60, p = 0.032). Stratification of MPZ variants into destabilizing and non-destabilizing is crucial for predicting severity and prognosis and tailoring therapeutic strategies. This approach has significant implications for upcoming UPR-modulating treatments and underscores the necessity of integrating molecular and clinical insights for optimal patient care.

1 November 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
LBLuca Bosco
Luca Bosco
CLChristian Laurini
Christian Laurini
LALuca Angelini
Luca Angelini
MBMarco Bosco
Marco Bosco
ARAdele Ratti
Adele Ratti
UCUbaldo Del Carro
Ubaldo Del Carro

4 November 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
ARAdele Ratti
Adele Ratti
LBLuca Bosco
Luca Bosco
CLChristian Laurini
Christian Laurini
LALuca Angelini
Luca Angelini
BSBenedetta Sorrenti
Benedetta Sorrenti
YFYuri Matteo Falzone
Yuri Matteo Falzone
Purpose of ReviewCranial neuropathies are a frequent reason for neurologic consultation, yet they remain diagnostically challenging because of a broad etiologic spectrum and overlapping clinical pr...

1 April 2026 in Neurology Genetics
Verified
Journal Article
Open access
ARAlessandra Rocco
Alessandra Rocco
CLChristian Laurini
Christian Laurini
YFYuri Matteo Falzone
Yuri Matteo Falzone
SCSilvia Calzavara
Silvia Calzavara
UCUbaldo Del Carro
Ubaldo Del Carro
FMFrancesca Maltecca
Francesca Maltecca
The AFG3L2 gene encodes a mitochondrial AAA-protease involved in inner mitochondrial membrane (IMM) proteostasis. Heterozygous variants in the AFG3L2 proteolytic domain cause Spinocerebellar Ataxia type 28, heterozygous variants in the AFG3L2 ATPase domain cause Optic Atrophy type 12, while biallelic variants lead to recessive Spastic Ataxia type 5. In this study, we aimed to investigate the link between AFG3L2 haploinsufficiency and Charcot-Marie-Tooth (CMT) phenotypes. We performed clinical evaluation, genetic analyses, electrophysiology, and functional studies in 1 patient's fibroblasts. In this study, we report a patient presenting with progressive symmetric distal muscle atrophy, weakness, pes cavus, and sensory deficits at lower limbs, in the absence of cerebellar or pyramidal signs. Electrophysiologic studies confirmed axonal sensorimotor neuropathy. After excluding common CMT-related genes, clinical exome sequencing revealed a heterozygous truncating variant in AFG3L2 [NM_006793.3:c.121C > T; p.(Arg41*)]. In patient's fibroblasts, we observed ∼50% reduction in AFG3L2 protein levels, which is sufficient to hyperactivate the stress-sensitive IMM protease OMA1. Consequently, we detected increased OPA1 processing, mitochondrial shortening, and activation of the integrated stress response. These findings suggest that AFG3L2 haploinsufficiency can underlie axonal CMT, expanding the clinical spectrum of AFG3L2-related diseases and emphasizing its potential inclusion in CMT diagnostic panels.

15 November 2026 in Muscle & Nerve
Verified
Journal Article
Closed access
ARAdele Ratti
Adele Ratti
MYMona Rita Yacoub
Mona Rita Yacoub
ACAlessandra Criscuoli
Alessandra Criscuoli
GGGiovanni Gaiera
Giovanni Gaiera
NANicoletta Anzalone
Nicoletta Anzalone
SPStefano Previtali
Stefano Previtali